NEW YORK and AMSTERDAM, Nov. 13, 2025 — Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “the Company”), a clinical-stage biopharmaceutical firm dedicated to improving patient outcomes through the development of effective, fast-acting, and convenient mental health treatments, today disclosed that its Co-Founder and Chief Executive Officer, Srinivas Rao, M.D., Ph.D., along with Kevin Craig, M.D., Chief Medical Officer, are slated to attend the Jefferies Global Healthcare Conference in London, UK. The specifics of the company’s involvement are:
Format: A fireside chat and individual investor meetings
Date and Time: The fireside chat will occur on Thursday, November 20, at 11:30 A.M. GMT/ 6:30 A.M. ET
Webcast link:
A recorded replay will be accessible in the Investors section of the AtaiBeckley website under for a duration of up to 90 days.
About Atai Beckley N.V.
AtaiBeckley operates as a clinical-stage biopharmaceutical company, committed to revolutionizing patient health by formulating impactful, swift-acting, and accessible mental health treatments. Its formation stemmed from the strategic merger of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s current portfolio of innovative therapies comprises BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) also for TRD, and EMP-01 (oral R-MDMA) for social anxiety disorder, all of which are progressing through Phase 2 clinical development. The company is additionally furthering a drug discovery initiative aimed at identifying novel, non-hallucinogenic 5-HT2AR agonists for both opioid use disorder and TRD. These initiatives are designed to forge new frontiers in mental health by delivering efficacious, commercially viable, and convenient interventional psychiatry treatments that can be smoothly integrated into healthcare systems.
For up-to-date information and to delve deeper into AtaiBeckley’s mission, please visit its website at or engage with the Company on and on .
Contact Information
Investor Contact:
Media Contact:
